Synairgen PLC (LON:SNG) said a trial of its treatment for people with coronavirus (COVID-19) is being expanded nationally with participants receiving the inhaled drug in their homes.
Meanwhile, results from the study of 100 patients successfully treated with the SNG001 treatment in hospital are set to be released next month.
The roll-out of the trial beyond Southampton will be supervised via daily video calls with a doctor or nurse.
The clinical assessment itself will test the effectiveness of SNG001 on patients identified earlier in the disease progression. And it will also generate valuable experience in the design and practical delivery of a model of remote care for at-risk patients.
“Not only does the home setting trial design allow us to test the drug much earlier in the illness, possibly preventing the worsening of symptoms, but it also reduces the infection risk for both patients and front-line workers due to its virtual format,” Synairgen chief executive Richard Marsden said in a statement.
“We also believe this novel trial design presents a practical way to utilise SNG001 in a real-world primary care setting.”
It is an inhaled interferon beta drug candidate designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.
Earlier studies have shown treatment activated antiviral pathways in the lung along with improving lung function for sufferers with a respiratory viral infection. The drug is also well tolerated.
Synairgen's phase II trial in COVID-19 patients is a double-blind, placebo-controlled trial that started with an initial 100 people before being widened to the home environment.
The shares were trading 4% higher at 40.50p in the late morning.
---adds share price and trial link---